CL2007003176A1 - Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis. - Google Patents
Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis.Info
- Publication number
- CL2007003176A1 CL2007003176A1 CL200703176A CL2007003176A CL2007003176A1 CL 2007003176 A1 CL2007003176 A1 CL 2007003176A1 CL 200703176 A CL200703176 A CL 200703176A CL 2007003176 A CL2007003176 A CL 2007003176A CL 2007003176 A1 CL2007003176 A1 CL 2007003176A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- 11betahsd1
- aterosclerosis
- nicotinamide
- obesity
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 208000001145 Metabolic Syndrome Diseases 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 title 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86430306P | 2006-11-03 | 2006-11-03 | |
| US86424706P | 2006-11-03 | 2006-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2007003176A1 true CL2007003176A1 (es) | 2008-07-25 |
Family
ID=39304797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200703176A CL2007003176A1 (es) | 2006-11-03 | 2007-11-02 | Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis. |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US7964618B2 (enExample) |
| EP (2) | EP2086939B8 (enExample) |
| JP (1) | JP5165688B2 (enExample) |
| KR (1) | KR101465275B1 (enExample) |
| CN (3) | CN101573336B (enExample) |
| AR (1) | AR063458A1 (enExample) |
| AT (1) | ATE475649T1 (enExample) |
| AU (1) | AU2007315955B2 (enExample) |
| BR (1) | BRPI0717970C1 (enExample) |
| CA (1) | CA2668006C (enExample) |
| CL (1) | CL2007003176A1 (enExample) |
| CO (1) | CO6321130A2 (enExample) |
| CY (1) | CY1110813T1 (enExample) |
| DE (1) | DE602007008137D1 (enExample) |
| DK (1) | DK2086939T3 (enExample) |
| ES (2) | ES2423206T3 (enExample) |
| HR (1) | HRP20100522T1 (enExample) |
| IL (1) | IL198231A0 (enExample) |
| MX (1) | MX2009004707A (enExample) |
| NO (1) | NO20091603L (enExample) |
| NZ (1) | NZ576501A (enExample) |
| PE (1) | PE20081487A1 (enExample) |
| PL (1) | PL2086939T3 (enExample) |
| PT (1) | PT2086939E (enExample) |
| RS (1) | RS51451B (enExample) |
| RU (1) | RU2451674C2 (enExample) |
| SI (1) | SI2086939T1 (enExample) |
| TW (1) | TW200827346A (enExample) |
| UY (1) | UY30681A1 (enExample) |
| WO (1) | WO2008053194A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007058346A1 (ja) | 2005-11-21 | 2007-05-24 | Shionogi & Co., Ltd. | I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物 |
| TW200827346A (en) * | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| TW200836719A (en) * | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
| DK2163543T3 (en) | 2007-05-18 | 2015-04-27 | Shionogi & Co | Nitrogenholdigt heterocyklisk derivat med 11beta-hydroxysteroiddehydrogenase-type 1-inhibitorisk aktivitet |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP5441705B2 (ja) * | 2007-10-15 | 2014-03-12 | 武田薬品工業株式会社 | アミド化合物およびその用途 |
| WO2009056881A1 (en) * | 2007-10-29 | 2009-05-07 | Astrazeneca Ab | Chemical compounds 313 |
| WO2009098501A1 (en) * | 2008-02-04 | 2009-08-13 | Astrazeneca Ab | Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid |
| CA2719936A1 (en) * | 2008-04-22 | 2009-10-29 | Astrazeneca Ab | Substituted pyrimidin-5-carboxamides 281 |
| EP2243479A3 (en) | 2009-04-20 | 2011-01-19 | Abbott Laboratories | Novel amide and amidine derivates and uses thereof |
| JP2012529535A (ja) | 2009-06-12 | 2012-11-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼモジュレーターとして有用なニコチンアミド化合物 |
| WO2011049520A1 (en) * | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Adamantyl iminocarbonyl-substituted pyrimidines as inhibitors of 1 1 betahsd1 |
| CA2780908A1 (en) * | 2009-11-24 | 2011-06-03 | Allergan, Inc. | Novel compounds as receptor modulators with therapeutic utility |
| WO2011068927A2 (en) * | 2009-12-04 | 2011-06-09 | Abbott Laboratories | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| KR20110123657A (ko) * | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| US9464078B2 (en) | 2010-09-23 | 2016-10-11 | Abbvie Inc. | Monohydrate of azaadamantane derivatives |
| US8471027B2 (en) * | 2011-04-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Adamantyl compounds |
| US8980904B2 (en) * | 2011-07-21 | 2015-03-17 | Xuanzhu Pharma Co., Ltd. | Heterocyclic substituted pyrimidine compound |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN102659657B (zh) * | 2012-04-24 | 2014-08-06 | 徐州医学院 | 一种蛋白酶抑制剂pf429242的合成方法 |
| BR112014031108A2 (pt) | 2012-06-20 | 2017-06-27 | Hoffmann La Roche | compostos de pirazol substituído como antagonistas de lpar |
| HK1206342A1 (en) | 2012-06-20 | 2016-01-08 | 霍夫曼-拉罗奇有限公司 | N-alkyltriazole compounds as lpar antagonists |
| EP3821892A1 (en) | 2019-11-12 | 2021-05-19 | University of Leeds | (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds |
| GB202216324D0 (en) * | 2022-11-02 | 2022-12-14 | Cerevance Ltd | Novel compounds |
| GB202408335D0 (en) | 2024-06-11 | 2024-07-24 | Astrazeneca Ab | Therapies for wound treatment |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR66581B (enExample) | 1978-02-21 | 1981-03-27 | Delalande Sa | |
| CA1307786C (en) | 1984-12-14 | 1992-09-22 | Keiichi Yokoyama | Quinazoline derivatives and antihypertensive preparations containing same as effective components |
| ES2283315T3 (es) | 1999-09-16 | 2007-11-01 | Tanabe Seiyaku Co., Ltd. | Compuestos ciclicos de 6 miembros que contienen nitrogeno aromatico. |
| FR2803592A1 (fr) * | 2000-01-06 | 2001-07-13 | Aventis Cropscience Sa | Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant. |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| US6777446B2 (en) | 2000-09-05 | 2004-08-17 | Tularik, Inc. | FXR modulators |
| WO2002034711A1 (en) | 2000-10-20 | 2002-05-02 | Biocryst Pharmaceuticals, Inc. | Biaryl compounds as serine protease inhibitors |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| WO2003086410A1 (en) | 2002-04-05 | 2003-10-23 | The University Of Edinburgh | Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent |
| WO2004039795A2 (en) * | 2002-10-29 | 2004-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds for the treatment of hyperlipidemia |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| SE0300457D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
| SE0300458D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
| MXPA05009059A (es) | 2003-02-26 | 2005-10-19 | Banyu Pharma Co Ltd | Derivados de heteroarilcarbamoilbenceno. |
| ATE482747T1 (de) | 2003-04-11 | 2010-10-15 | High Point Pharmaceuticals Llc | Neue amide derivate und deren pharmazeutische verwendungen |
| CN1832741A (zh) | 2003-08-07 | 2006-09-13 | 默克公司 | 作为11－β－羟甾类脱氢酶－1抑制剂的吡唑甲酰胺类 |
| MXPA06002853A (es) | 2003-09-11 | 2006-06-14 | Kemia Inc | Inhibidores citoquina. |
| GB0327761D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
| BRPI0417687A (pt) | 2003-12-19 | 2007-04-03 | Pfizer | derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade |
| JP2007523206A (ja) | 2004-02-24 | 2007-08-16 | グラクソ グループ リミテッド | Ｃｂ２受容体モジュレーターとしてのピリジン誘導体およびその使用 |
| CN1972914A (zh) * | 2004-03-31 | 2007-05-30 | 詹森药业有限公司 | 作为组胺h3受体配合体的非咪唑杂环化合物 |
| EP1745019A1 (en) | 2004-05-06 | 2007-01-24 | Pfizer Inc. | Novel compounds of proline and morpholine derivatives |
| TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| RU2375351C2 (ru) | 2004-06-28 | 2009-12-10 | Ф.Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩИМ ДЕЙСТВИЕМ В ОТНОШЕНИИ 11b-HSD1 |
| US20090093463A1 (en) | 2004-11-02 | 2009-04-09 | Agouron Pharmaceuticals Inc. | Novel compounds of substituted and unsubtituted adamantyl amides |
| WO2006050476A2 (en) | 2004-11-03 | 2006-05-11 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as ion channel modulators and methods of use |
| KR101496190B1 (ko) | 2005-01-05 | 2015-02-26 | 애브비 인코포레이티드 | 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체 |
| WO2006106052A1 (en) | 2005-04-05 | 2006-10-12 | F. Hoffmann-La Roche Ag | Pyrazoles |
| BRPI0609685A2 (pt) | 2005-04-06 | 2010-04-20 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para tratamento e/ou profilaxia de enfermidades que estão associados com a modulação de receptores de cb1, e utilização dos mesmos |
| WO2006106423A2 (en) | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
| EP2527337A1 (en) | 2005-04-14 | 2012-11-28 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
| US20110059941A1 (en) | 2005-05-24 | 2011-03-10 | Peter William Rodney Caulkett | 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators |
| US8952176B2 (en) | 2005-06-07 | 2015-02-10 | Shionogi & Co., Ltd. | Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity |
| EP1889842A4 (en) | 2005-06-08 | 2009-07-29 | Japan Tobacco Inc | HETEROCYCLIC CONNECTION |
| EA200702498A1 (ru) | 2005-06-16 | 2008-06-30 | Пфайзер Инк. | N-(пиридин-2-ил)сульфонамидные производные |
| NZ564608A (en) | 2005-07-09 | 2009-09-25 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| US20100160286A1 (en) | 2005-08-09 | 2010-06-24 | Astrazeneca Uk Limited Ab | Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes |
| CA2627813A1 (en) | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted pyrrolones as allosteric modulators of glucokinase |
| WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| WO2007058346A1 (ja) | 2005-11-21 | 2007-05-24 | Shionogi & Co., Ltd. | I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物 |
| KR20080091503A (ko) | 2006-01-31 | 2008-10-13 | 인사이트 코포레이션 | 아미도 화합물 및 약제로서의 이의 용도 |
| SI1999114T1 (sl) | 2006-03-22 | 2015-10-30 | F. Hoffmann-La Roche Ag | Pirazoli kot 11-beta-hsd-1 |
| KR20090014347A (ko) | 2006-04-07 | 2009-02-10 | 하이 포인트 파마슈티칼스, 엘엘씨 | 11β-히드록시스테로이드 탈수소효소 타입 1 활성 화합물 |
| RU2008146591A (ru) | 2006-04-27 | 2010-06-10 | Зольвай Фармасьютиклз Гмбх (De) | Применение модуляторов каннабиноидного рецептора свх в качестве модуляторов калиевых каналов |
| US20100022589A1 (en) | 2006-07-27 | 2010-01-28 | Mccoull William | Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase |
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| TW200836719A (en) | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
| DK2163543T3 (en) | 2007-05-18 | 2015-04-27 | Shionogi & Co | Nitrogenholdigt heterocyklisk derivat med 11beta-hydroxysteroiddehydrogenase-type 1-inhibitorisk aktivitet |
| RU2440989C2 (ru) | 2007-07-17 | 2012-01-27 | Ф.Хоффманн-Ля Рош Аг | ИНГИБИТОРЫ 11β-ГИДРОКСИСТЕРОИДНОЙ ДЕГИДРОГЕНАЗЫ |
| EP2217232A1 (en) | 2007-11-06 | 2010-08-18 | AstraZeneca AB | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465 |
| WO2009098501A1 (en) | 2008-02-04 | 2009-08-13 | Astrazeneca Ab | Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid |
| CA2719936A1 (en) | 2008-04-22 | 2009-10-29 | Astrazeneca Ab | Substituted pyrimidin-5-carboxamides 281 |
| CN102300851A (zh) | 2009-01-30 | 2011-12-28 | 阿斯利康(瑞典)有限公司 | 制备含羧基的吡唑酰氨基化合物597的新方法 |
| WO2011049520A1 (en) * | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Adamantyl iminocarbonyl-substituted pyrimidines as inhibitors of 1 1 betahsd1 |
-
2007
- 2007-10-29 TW TW096140633A patent/TW200827346A/zh unknown
- 2007-10-30 US US11/928,744 patent/US7964618B2/en active Active
- 2007-10-31 AU AU2007315955A patent/AU2007315955B2/en active Active
- 2007-10-31 CN CN2007800491675A patent/CN101573336B/zh not_active Expired - Fee Related
- 2007-10-31 UY UY30681A patent/UY30681A1/es not_active Application Discontinuation
- 2007-10-31 DE DE602007008137T patent/DE602007008137D1/de active Active
- 2007-10-31 NZ NZ576501A patent/NZ576501A/en not_active IP Right Cessation
- 2007-10-31 MX MX2009004707A patent/MX2009004707A/es active IP Right Grant
- 2007-10-31 CN CN2012100119350A patent/CN102603711A/zh active Pending
- 2007-10-31 PL PL07824375T patent/PL2086939T3/pl unknown
- 2007-10-31 ES ES10163730T patent/ES2423206T3/es active Active
- 2007-10-31 EP EP07824375A patent/EP2086939B8/en active Active
- 2007-10-31 CA CA2668006A patent/CA2668006C/en active Active
- 2007-10-31 RS RSP-2010/0422A patent/RS51451B/sr unknown
- 2007-10-31 CN CN2010101438299A patent/CN101787016B/zh active Active
- 2007-10-31 JP JP2009535119A patent/JP5165688B2/ja active Active
- 2007-10-31 ES ES07824375T patent/ES2347491T3/es active Active
- 2007-10-31 WO PCT/GB2007/004131 patent/WO2008053194A2/en not_active Ceased
- 2007-10-31 SI SI200730335T patent/SI2086939T1/sl unknown
- 2007-10-31 AT AT07824375T patent/ATE475649T1/de active
- 2007-10-31 EP EP10163730.4A patent/EP2233480B1/en active Active
- 2007-10-31 KR KR1020097010339A patent/KR101465275B1/ko active Active
- 2007-10-31 PT PT07824375T patent/PT2086939E/pt unknown
- 2007-10-31 BR BRPI0717970A patent/BRPI0717970C1/pt active IP Right Grant
- 2007-10-31 DK DK07824375.5T patent/DK2086939T3/da active
- 2007-10-31 RU RU2009115830/04A patent/RU2451674C2/ru active
- 2007-10-31 HR HR20100522T patent/HRP20100522T1/hr unknown
- 2007-11-02 AR ARP070104887A patent/AR063458A1/es not_active Application Discontinuation
- 2007-11-02 CL CL200703176A patent/CL2007003176A1/es unknown
- 2007-11-05 PE PE2007001517A patent/PE20081487A1/es not_active Application Discontinuation
-
2009
- 2009-04-20 IL IL198231A patent/IL198231A0/en unknown
- 2009-04-22 NO NO20091603A patent/NO20091603L/no not_active Application Discontinuation
- 2009-04-29 CO CO09043382A patent/CO6321130A2/es not_active Application Discontinuation
- 2009-08-14 US US12/541,574 patent/US20090312372A1/en not_active Abandoned
- 2009-08-14 US US12/541,565 patent/US8673938B2/en not_active Expired - Fee Related
-
2010
- 2010-10-04 CY CY20101100879T patent/CY1110813T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008000067A1 (es) | Compuestos derivados de espirocromanona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, higado graso, hiperlipemia, obesidad, diabetes, bulimia, neoplasma maligno o enfermedades infecciosas. | |
| CL2007002972A1 (es) | Compuestos derivados de imidazolona e imidazolidinona, inhibidores de la 11b-hsd1; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para el tratamiento y prevencion de diabetes, obesidad, trastornos alimentarios, disl | |
| CL2007002187A1 (es) | Compuestos derivados espirocetal sustituidos; composicion farmaceutica que comprende a dicho compuesto; y su uso para el tratamiento de la diabetes, hiperglicemia, complicaciones diabeticas y obesidad. | |
| CL2007001778A1 (es) | Compuestos derivados de 2-pirazinacarboxamida, antagonistas/agonistas inversos selectivos de cb1; proceso de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de trastornos de ingestion de comida, diabetes tipo ii y a | |
| CL2007003423A1 (es) | Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda | |
| CL2008000197A1 (es) | Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
| CL2007003802A1 (es) | Compuestos derivados de piperidina, inhibidores de la sintasa de acidos grasos; procedimiento de preparacion de dichos compuestos; y su uso para tratar la obesidad o el sobrepeso. | |
| IL195030A (en) | Dpp iv inhibitor formulations | |
| CL2007003722A1 (es) | Compuestos derivados de propionamida n-sustituida por heterociclo, activadores de glucoquinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento o prevencion de la diabetes. | |
| CY1109842T1 (el) | Αναστολεις της αφυδρογονασης 11-β-υδροξυστεροειδων i | |
| CL2011001497A1 (es) | Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico. | |
| CL2012001043A1 (es) | Compuestos derivados de hexahidroindenopiridina y/o octahidrobenzoquinolina, inhibidores de 11ß-hidroxiesteroide deshidrogenasa 1 (hsd 1); composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos para la preparacion de medicamentos para el tratamiento de trastornos metabolicos. | |
| BRPI0817028A2 (pt) | composto inibidor de diacilglicerol acil tranferase, composição farmacêutica que o contém, uso do composto, métodos para o tratamento ou profilaxia de diabetes, obesidade, distúrbios de alimentação e dislidemias e diabetes do tipo ii | |
| CL2007003226A1 (es) | Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer. | |
| BRPI0811947A2 (pt) | Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratamento de obesidade, diabetes do tipo ii, dislipidemia ou síndrome metabólica | |
| CL2007001945A1 (es) | Compuestos derivados de alquilpiridazina, inhibidores de 11 beta-hsd1; proceso de obtencion de los compuestos; composicion farmaceutica que los comprenden; y usos en el tratamiento de la diabetes, obesidad, trastorno de ingestion de comida, dislipide | |
| CL2007003299A1 (es) | Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| CL2007002841A1 (es) | Compuestos derivados de indol, antagonistas del receptor de glucagion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes mellitus tipo 2, hiperglucemia, diabetes o resistencia a la insulina. | |
| CL2008000316A1 (es) | Compuestos derivados de 2-metilsulfonil-1,2,3,4-tetrahidroisoquinolina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la diabetes, hiperlipidemia, enfermedades cardiacas, artritis, osteoporosis, hipertension, catara | |
| EA200870472A1 (ru) | Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1 | |
| DE602007007211D1 (de) | Inhibitoren von11-beta-hydroxysteroiddehydrogenase 1 | |
| CL2008003407A1 (es) | Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1. | |
| CL2007003202A1 (es) | Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular. | |
| CL2009000309A1 (es) | Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2. | |
| CL2007001530A1 (es) | Compuestos derivados de tiazol, inhibidores de fbpasa; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de diabetes mellitus tipo i, ii y iii, desequilibrio de glucosa en ayunas, desequilibrio en la tolerancia de la glucosa y complicaciones de la diabetes. |